IRIS
MISSALE, Gabriele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.154
NA - Nord America 7.057
EU - Europa 4.107
SA - Sud America 1.162
AF - Africa 438
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 8
Totale 19.942
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.863
SG - Singapore 2.748
CN - Cina 1.710
VN - Vietnam 1.131
BR - Brasile 909
IE - Irlanda 828
IT - Italia 789
SE - Svezia 668
HK - Hong Kong 573
DE - Germania 399
FR - Francia 382
ZA - Sudafrica 295
NL - Olanda 230
FI - Finlandia 209
TR - Turchia 205
IN - India 149
GB - Regno Unito 116
RU - Federazione Russa 112
CA - Canada 109
AR - Argentina 98
BD - Bangladesh 82
UA - Ucraina 80
KR - Corea 73
AT - Austria 65
IQ - Iraq 65
JP - Giappone 65
MX - Messico 52
ID - Indonesia 44
PH - Filippine 40
CI - Costa d'Avorio 39
PL - Polonia 36
CO - Colombia 35
PK - Pakistan 34
VE - Venezuela 33
BE - Belgio 32
EC - Ecuador 28
ES - Italia 28
UZ - Uzbekistan 28
TH - Thailandia 24
KE - Kenya 22
MA - Marocco 22
CZ - Repubblica Ceca 21
TW - Taiwan 19
CL - Cile 17
LT - Lituania 17
MY - Malesia 17
PY - Paraguay 17
AE - Emirati Arabi Uniti 13
AU - Australia 13
AZ - Azerbaigian 12
EG - Egitto 12
GR - Grecia 12
JO - Giordania 11
RO - Romania 11
SA - Arabia Saudita 11
UY - Uruguay 11
IL - Israele 10
OM - Oman 10
IR - Iran 9
KZ - Kazakistan 9
PE - Perù 9
DK - Danimarca 8
PS - Palestinian Territory 8
TN - Tunisia 8
AL - Albania 7
CH - Svizzera 7
DZ - Algeria 7
KH - Cambogia 7
NP - Nepal 7
BG - Bulgaria 6
BY - Bielorussia 6
LV - Lettonia 6
PA - Panama 6
AM - Armenia 5
DO - Repubblica Dominicana 5
ET - Etiopia 5
EU - Europa 5
GE - Georgia 5
KG - Kirghizistan 5
LU - Lussemburgo 5
RS - Serbia 5
AO - Angola 4
BO - Bolivia 4
CR - Costa Rica 4
JM - Giamaica 4
LB - Libano 4
LY - Libia 4
PT - Portogallo 4
QA - Qatar 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
EE - Estonia 3
GT - Guatemala 3
HR - Croazia 3
HU - Ungheria 3
MN - Mongolia 3
SI - Slovenia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BN - Brunei Darussalam 2
CY - Cipro 2
Totale 19.898
Salva come PNG Salva come JPEG
Città #
Singapore 1.411
Ashburn 980
Dublin 828
San Jose 702
Chandler 620
Dallas 556
Santa Clara 555
Hong Kong 537
Beijing 393
Ho Chi Minh City 323
Hanoi 291
Johannesburg 274
Boardman 251
Parma 234
Ann Arbor 201
Dearborn 191
Shanghai 176
Los Angeles 172
New York 159
Lauterbourg 156
Princeton 147
Izmir 132
Nanjing 120
Munich 116
Wilmington 99
São Paulo 98
Hefei 88
Milan 79
Grafing 77
Helsinki 74
Jacksonville 70
Columbus 64
Moscow 59
Jinan 55
Council Bluffs 54
Seoul 54
Haiphong 53
Tokyo 52
Shenyang 51
Vienna 51
Des Moines 50
Da Nang 49
Bremen 43
Buffalo 42
Seattle 42
Frankfurt am Main 41
Chicago 40
Abidjan 39
Tianjin 37
Toronto 36
Turku 36
Bengaluru 34
Rio de Janeiro 34
Rome 34
The Dalles 34
Guangzhou 32
Hebei 32
Kunming 31
Montreal 31
Nuremberg 31
Bologna 30
Kocaeli 30
Warsaw 30
Nanchang 28
London 26
Orem 25
Brussels 24
Changsha 24
Jakarta 24
Reggio Emilia 24
Stockholm 24
Brooklyn 23
Redmond 23
Tashkent 23
Ardea 22
Phoenix 22
Jiaxing 21
Zhengzhou 21
Belo Horizonte 20
Amsterdam 19
Atlanta 19
Chennai 19
Denver 19
Dhaka 19
Houston 18
Hải Dương 18
Mexico City 18
Nairobi 18
Norwalk 18
San Mateo 18
Baghdad 17
Boston 17
Salvador 17
Düsseldorf 16
Hangzhou 16
Istanbul 16
Fairfield 15
Fremont 15
Woodbridge 15
Biên Hòa 14
Totale 12.176
Salva come PNG Salva come JPEG
Nome #
A novel enhancing effect of SARS-CoV-2 mutations on anti-viral CD8 T cell responses 303
FUNCTIONAL AND TRANSCRIPTIONAL RESTORATION OF EXHAUSTED VIRUS-SPECIFIC T LYMPHOCYTES FROM PATIENTS WITH CHRONIC HEPATITIS B 282
Role of immunoglobulin G fragment C receptor polymorphism-mediatedantibody-dependant1. cellular cytotoxicity in colorectal cancer treated withcetuximab therapy. Pharmacogenomics J. 282
Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection 252
HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B 245
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 216
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 210
A simplified sars-cov-2 pseudovirus neutralization assay 208
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 189
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 176
Anti-Viral Intrahepatic T-Cell Responses can be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B 175
Metabolic regulation of the HBV-specific T cell function 173
Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches 168
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 168
Natural heteroclitic-like peptides are generated by SARS-CoV-2 mutations 167
Activation of Natural Killer Cells During Acute Infection With Hepatitis C Virus 163
Deregulated intracellular pathways define novel molecular targets for HBV-specific CD8 T cell reconstitution in chronic hepatitis B 157
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B 156
Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter 156
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 155
Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B 154
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 153
Are Anti-TNF-α Agents Safe for Treating Psoriasis in Hepatitis C Virus Patients with Advanced Liver Disease? Case Reports and Review of the Literature 153
Cytotoxic T Cell response to Melanoma Associated Antigens (MAGE) in patients with Hepatocellular Carcinoma 152
Resolution of late-onset heart and liver failures after reversion of jejuno-ileal bypass: a case report 150
Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection 149
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 149
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 149
HBV immune-therapy: From molecular mechanisms to clinical applications 148
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors 146
Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation 145
Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma 145
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 144
Antiviral CD8-mediated responses in chronic HCV carriers with HBV superinfection 141
Correlation between LDH levels and response to sorafenib in HCC patients: An analysis of the ITA.LI.CA database 141
The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study 141
Ex vivo characterization of tumor-derived melanoma antigenencoding gene-specific CD8 1 cells in patientswith hepatocellular carcinoma 141
T cell regulation in HBV-related chronic liver disease 141
Antibody responses to hepatitis C virus hypervariable region 1: Evidence for cross-reactivity and immune-mediated sequence variation 140
L-Asparaginase and Inhibitors of Glutamine Synthetase DiscloseGlutamine Addiction of Beta-Catenin-Mutated Human HepatocellularCarcinoma Cells 138
The good and the bad of natural killer cells in virus control: Perspective for anti-HBV therapy 137
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 137
Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts 137
Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient 135
Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma 134
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer 132
Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection 131
Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro 131
Unraveling the multifaceted nature of cd8 t cell exhaustion provides the molecular basis for therapeutic t cell reconstitution in chronic hepatitis b and c 131
Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment 130
The changing scenario of hepatocellular carcinoma in Italy: an update 128
Targeting Stress Sensor Kinases in Hepatocellular Carcinoma-Infiltrating Human NK Cells as a Novel Immunotherapeutic Strategy for Liver Cancer 127
Immune gene expression profile in hepatocellular carcinoma and surrounding tissue predicts time to tumor recurrence 127
Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. 127
What Is the Current Status of Hepatitis B Virus Viro-Immunology? 126
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study 126
Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group 124
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use 124
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 124
Early kinetics of innate and adaptive immune responses during hepatitis B virus infection 122
Neoplastic macrovascular invasion represents an independent risk factor for dismal survival in sorafenib treatment for hepatocellular carcinoma 122
Infection of circulating and liver infiltrating T cells by hepatitis C virus of different subtypes 121
Cytotoxic T Cell response to Melanoma Associated Antigens (MAGE) in patients with Hepatocellular Carcinoma. 121
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 120
The evolutionary scenario of hepatocellular carcinoma in Italy: an update 120
Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B 120
Head-injured subjects aged over 50 years: correlations between variables of trauma and neuropsychologial follow-up 117
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 117
Integrated prognostication of intrahepatic cholangiocarcinoma by contrast-enhanced computed tomography: the adjunct yield of radiomics 116
[Surgical risks for cirrhotic patients] 116
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu-Positive Metastatic Breast Cancer. 115
AISF position paper on HCV in immunocompromised patients 114
TRANSCRIPTOME ANALYSIS OF EXHAUSTED VIRUS-SPECIFIC CD8 T CELLS IN CHRONIC HBV INFECTION IDENTIFIES PROFOUND METABOLIC AND FUNCTIONAL CELL DEFECTS 114
COMPOSTO E COMPOSIZIONE PER IL RIPRISTINO METABOLICO E FUNZIONALE DEI LINFOCITI NK NELL’EPATOCARCINOMA E RELATIVO METODO 113
Fine specificity of the human T cell response to hepatitis B virus core antigen 112
Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen 111
FluoroSpot assay to analyze SARS-CoV-2-specific T cell responses 111
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/NEU-positive metastatic breast cancer 110
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016) 107
Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. 107
Comparative pathogenesis of HBV and HCV 107
Etanercept in the treatment of psoriasis and psoriathic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients 107
Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine development 107
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro 107
Immune pathogenesis of hepatitis B 106
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma 106
Oral lichen planus infiltrating T-cells:a Pathogenetic role for HCV-specific T cell responses? 105
Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial 105
Intratumor Regulatory Noncytotoxic NK Cells in Patients with Hepatocellular Carcinoma 105
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 103
In reply 103
The surgical risk in cirrhosis of the liver 103
Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection 101
The Characteristics of the Cell-Mediated Immune Response Identify Different Profiles of Occult Hepatitis B Virus Infection 100
Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor 100
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV 100
Role of viral and host factors in HCV persistence: Which lesson for therapeutic and preventive strategies? 99
Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein 99
Nitrogen balance in the assessment of cirrhotic patients 97
Combination of radiofrequency ablation and immunotherapy 97
Totale 13.872
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.941
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.941
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021159 0 0 0 0 0 0 0 0 0 70 54 35
2021/2022727 19 21 26 53 47 91 38 54 36 21 44 277
2022/20232.802 318 250 185 172 168 298 53 157 988 25 116 72
2023/20241.260 72 122 42 57 113 292 85 88 46 74 92 177
2024/20254.417 91 221 279 233 492 548 224 198 576 421 361 773
2025/20268.679 830 877 1.142 850 1.268 489 1.017 311 1.248 647 0 0
Totale 20.243